Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Calgary
$150,000.00
Cost-Effectiveness Analysis of Probiotics for the Primary Prevention of Clostridium difficile Infections
FY 2015-16
Summary
Clostridium difficile infections (aka C-diff) is the most frequently identified cause of hospital-acquired diarrhea. It can be a mild infection with just diarrhea or it can result in severe dehydration, septic shock and death. This infection complicates and prolongs hospital stays and impacts resources and costs in the healthcare system. The most common way patients develop C-diff is through increased antibiotic use and weakened immune systems while in hospital. When patients are given antibiotics to treat other infections they can upset the balance of organisms in their intestine, allowing the bug that causes C-diff to grow and lead to infection. Probiotics are live organisms, considered to be "good bacteria" and are thought to improve the balance of organisms in the intestine and reduce the risk of the C-diff causing infection. Therefore, it has been proposed that giving patients a probiotic if they are on antibiotics while in hospital may reduce the risk of developing C-diff and thus would decrease hospital stays and costs.
There are many patients on antibiotics in hospital, so introducing probiotics for these patients would cost a significant amount of money. Furthermore, it is not clear whether probiotics will decrease the occurrence of C-diff enough to result in cost-savings. Therefore, an economic evaluation assessing the costs and consequences related to probiotic use is needed. The various factors that need to be considered include the cost of probiotics, how well the probiotic works in reducing the risk of C-diff, and the cost of treating and managing C-diff patients in hospital.
This study is important because it will determine whether it is worth investing in probiotics to reduce the risk of C-diff among hospitalized patients.
Department
Program
Doctoral: Vanier Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
339760
Name
Leal Jenine R
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Cost-Effectiveness Analysis of Probiotics for the Primary Prevention of Clostridium difficile Infections
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Clostridium Difficile; Cost-Effectiveness Analysis; Economic Evaluation; Epidemiology; Inpatients; Probiotics
Abstract
Clostridium difficile infections (aka C-diff) is the most frequently identified cause of hospital-acquired diarrhea. It can be a mild infection with just diarrhea or it can result in severe dehydration, septic shock and death. This infection complicates and prolongs hospital stays and impacts resources and costs in the healthcare system. The most common way patients develop C-diff is through increased antibiotic use and weakened immune systems while in hospital. When patients are given antibiotics to treat other infections they can upset the balance of organisms in their intestine, allowing the bug that causes C-diff to grow and lead to infection. Probiotics are live organisms, considered to be "good bacteria" and are thought to improve the balance of organisms in the intestine and reduce the risk of the C-diff causing infection. Therefore, it has been proposed that giving patients a probiotic if they are on antibiotics while in hospital may reduce the risk of developing C-diff and thus would decrease hospital stays and costs.
There are many patients on antibiotics in hospital, so introducing probiotics for these patients would cost a significant amount of money. Furthermore, it is not clear whether probiotics will decrease the occurrence of C-diff enough to result in cost-savings. Therefore, an economic evaluation assessing the costs and consequences related to probiotic use is needed. The various factors that need to be considered include the cost of probiotics, how well the probiotic works in reducing the risk of C-diff, and the cost of treating and managing C-diff patients in hospital.
This study is important because it will determine whether it is worth investing in probiotics to reduce the risk of C-diff among hospitalized patients.
Competitiondate
201511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Leal, Jenine R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~